$47.87
3.477.82%
Last update: Nov 9, 7:28 PM
Liquidia Corp
LQDANASDAQ
Liquidia rose 75.6% from $27.26 to $47.87, ahead of the S&P 500's +10.5%. Its worst day was Sep 30 (−57.2%), and its low came Oct 6 at $25.91.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $0.15 missed the $0.33 estimate on $92.0M revenue (est. $79.3M).
+0.4% · S&P 500 −0.6%
EPS of $0.52 beat the $0.39 estimate on $132.9M revenue (est. $117.3M).
Story events cover the past 12 months · Times ET
+25.6% · S&P 500 +0.2%
EPS of $0.74 missed the $0.81 estimate on $171.7M revenue (est. $167.8M).
−10.5% · S&P 500 +0.3%
Liquidia closed at its lowest level of the year, 5.0% below where the year started.
−6.3% · S&P 500 +0.5%
Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced that it has entered
+26.6%, the year's best day · S&P 500 −1.1%
Where it ended: a close of $47.87 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 10, 2026 (EPS est. $0.93, revenue est. $208.6M).
Nothing in the past 12 months.
All LQDA dividend historyReplay the year: the line draws itself and stops at each of the 5 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for LQDA and SPY from Benzinga historical bars. Not investment advice.
